Alnylam Pharmaceuticals, Inc. (LON:0HD2)

Market Cap	33.05B +16.1%
Revenue (ttm)	2.76B +65.2%
Net Income	233.11M
EPS	1.73
Shares Out	n/a
PE Ratio	141.76
Forward PE	33.60
Dividend	n/a
Ex-Dividend Date	n/a

Volume	45
Average Volume	241
Open	344.00
Previous Close	337.94
Day's Range	335.00 - 345.41
52-Week Range	209.75 - 500.21
Beta	0.32
RSI	46.39
Earnings Date	Feb 12, 2026

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute hepatic porphyria; and OXLUMO for primary hyperoxaluria type 1. It also develops a range of products in Phase 3 trial, such as Nucresiran for ATTR amylo...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 2002
• Employees: 2,500
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0HD2

Financial Performance

Financial numbers in USD